compound 2 [PMID: 28621538]   Click here for help

GtoPdb Ligand ID: 11282

Synonyms: example 727 [WO2012093101A1]
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 2 is a small molecule complement factor D inhibitor that has been developed by Novartis [1]. The compound is orally bioavailable, and blocks activation of the complement alternative pathway in vitro and in vivo. Factor D inhibitors act upstream of the factor C5-targeting drugs such as eculizumab and ravulizumab, and small molecules are intended to offer more flexible therapeutic options than the existing monoclonal antibodies.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 123.21
Molecular weight 482.07
XLogP 1.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Brc1cccc(n1)NC(=O)[C@@H]1C[C@@H]2[C@H](N1C(=O)Cn1nc(c3c1cccc3)C(=O)N)C2
Isomeric SMILES Brc1cccc(n1)NC(=O)[C@@H]1C[C@@H]2[C@H](N1C(=O)Cn1nc(c3c1cccc3)C(=O)N)C2
InChI InChI=1S/C21H19BrN6O3/c22-16-6-3-7-17(24-16)25-21(31)15-9-11-8-14(11)28(15)18(29)10-27-13-5-2-1-4-12(13)19(26-27)20(23)30/h1-7,11,14-15H,8-10H2,(H2,23,30)(H,24,25,31)/t11-,14-,15+/m1/s1
InChI Key CWZUTHDJLNZLCM-DFBGVHRSSA-N
References
1. Lorthiois E, Anderson K, Vulpetti A, Rogel O, Cumin F, Ostermann N, Steinbacher S, Mac Sweeney A, Delgado O, Liao SM et al.. (2017)
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
J Med Chem, 60 (13): 5717-5735. [PMID:28621538]